Antibody-Drug Conjugates Are ‘Changing Outcomes’ in HR+ HER2– Breast Cancer

Video
Conference|ASCO Breast Cancer Symposium

Sara M. Tolaney, MD, MPH, discusses how, compared with antibody-drug conjugates, chemotherapy produces low response rates and disease control in the treatment of those with hormone receptor–positive, HER2-negative metastatic breast cancer.

At the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, Sara M. Tolaney, MD, MPH, spoke with CancerNetwork® about how findings from the phase 3 TROPiCS-02 study (NCT03901339) highlight the ability of sacituzumab govitecan-hziy (Trodelvy) to improve patient outcomes over chemotherapy among those with hormone receptor–positive, HER2-negative metastatic breast cancer.

Tolaney, chief of the Division of Breast Oncology and associate director of the Susan F. Smith Center for Women’s Cancer at Dana-Farber Cancer Institute, and associate professor of medicine at Harvard Medical School, in Boston, discussed the low response rates and short duration of disease control associated with single agent chemotherapy in the aforementioned population.

In the TROPiCs-02 study, investigators reported a median overall survival (OS) of 14.5 months with sacituzumab vs 11.2 months with chemotherapy of physician’s choice (Hazard ratio, 0.79; 95% CI, 0.65-0.95; P = .0133).Additionally, the 12-month, 18-month, and 24-month OS rates among patients receiving sacituzumab vs those receiving chemotherapy were 60.9% (95% CI, 54.8%-66.4%) vs47.1% (95% CI, 41.0%-53.0%), 39.2% (95% CI, 33.4%-45.0%) vs 31.7% (95% CI, 26.2%-37.4%), and 25.6% (95% CI, 20.4%-31.2%) vs 21.1% (95% CI, 16.3%-26.3%), respectively.

Transcript:

It's really exciting to see that antibody-drug conjugates are changing outcomes for patients. We've been so used to seeing single agent chemotherapy being given sequentially in this pretreated setting, and, unfortunately, it has been associated with low response rates and short duration of disease control.

These data looking at sacituzumab can tell us that we do have new agents that do better than standard chemotherapy and are really improving outcomes for our patients.

Reference

Tolaney SM, Bardia A, Marmé F, et al. Final overall survival (OS) analysis from the phase 3 TROPiCS-02 study of sacituzumab govitecan (SG) in patients (pts) with hormone receptor–positive/HER2-negative (HR+/HER2–) metastatic breast cancer (mBC). J Clin Oncol. 2023;41(suppl 16):1003. doi:10.1200/JCO.2023.41.16_suppl.1003

Recent Videos
Standardizing surgical outcomes and better training oncologic surgeons may be accomplished through the use of AI.
The poly-ICLC trial seeks to develop a delivery mechanism to prostate cancer through different biomarkers.
Shwetal Mehta, PhD, describes efforts regarding the development of protein degraders and antibody-drug conjugates in the neuro-oncology field.
Liquid biopsy tests may help determine the extent of activity among patients who receive a novel fourth-generation EGFR inhibitor for brain cancer.
Shwetal Mehta, PhD, highlights novel brain cancer drug development procedures in the clinical lab and pre-clinical arms of the Ivy Brain Tumor Center.
Observing changes in the tumor microenvironment before and after a biopsy may elucidate how kidney cancer cells interact with immune cells.
Various kidney cancer trials have combined agents such as A2a receptor inhibitors with immunotherapy backbones to potentially improve treatment outcomes.
Leveraging novel agents, innovative clinical trial designs, and correlative studies may improve the treatment of patients with kidney cancer.
Sympathomimetic effects related to psilocybin may preclude use among patients with coronary artery disease or those with a high risk of stroke.
Related Content
FDA Grants Breakthrough Device Designation to Biosignature Test in DCIS

FDA Grants Breakthrough Device Designation to Biosignature Test in DCIS

Tim Cortese
January 18th 2025
Article

The DCISionRT test has shown to be a significant factor in a clinician’s recommendation on whether a patient with DCIS should receive radiotherapy.

Paolo Tarantino, MD, and Matteo Lambertini, MD, PhD discuss findings related to CDK4/6 inhibitors and antibody drug conjugates presented at SABCS 2024.

SABCS 2024 Data Show ‘Great Steps Forward’ in Breast Cancer Care

Paolo Tarantino, MD;Matteo Lambertini, MD
January 13th 2025
Podcast

Paolo Tarantino, MD, and Matteo Lambertini, MD, PhD discuss findings related to CDK4/6 inhibitors and antibody drug conjugates presented at SABCS 2024.

Data support the IGG signature, especially its key gene subset, as a potential marker of sustained antitumor activity in breast cancer.

High Immunoglobulin Expression Shows Long-Term Survival in Breast Cancer

Russ Conroy
January 14th 2025
Article

Data support the IGG signature, especially its key gene subset, as a potential marker of sustained antitumor activity in breast cancer.

A study evaluating disparities in breast reconstructive surgery sought to assess the impact of culture, race, and ethnicity in minority groups.

Reducing Post-Mastectomy Disparities in Breast Cancer Minority Populations

Rachel A. Greenup, MD, MPH
December 23rd 2024
Podcast

A study evaluating disparities in breast reconstructive surgery sought to assess the impact of culture, race, and ethnicity in minority groups.

The World Health Organization has approved emiltatug ledadotin as XMT-1660’s international nonproprietary name.

XMT-1660 Earns Fast Track Designation for HER2–Low/Negative Breast Cancer

Roman Fabbricatore
January 12th 2025
Article

The World Health Organization has approved emiltatug ledadotin as XMT-1660’s international nonproprietary name.

Elinzanetant Reduces The Frequency of Hot Flashes in HR+ Breast Cancer

Elinzanetant Reduces The Frequency of Hot Flashes in HR+ Breast Cancer

Tim Cortese
January 10th 2025
Article

Elinzanetant met all primary and secondary end points when compared with placebo in patients with HR-positive breast cancer in the phase 3 OASIS-4 trial.